Loading clinical trials...
Loading clinical trials...
An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different Injection Sites in Adult Male and Female Subjects With Type 2 Diabetes and of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy, Normal Volunteers
This study is an open-label study in healthy volunteers and in patients with Type 2 Diabetes Mellitus to assess safety and tolerability parameters, the levels of GSK716155 in the bloodstream after a single dose given at different injection sites, and the impact this medication has on various substances in the blood. Assessments include ECGs, vital signs, repeat blood sampling and monitoring of any side effects.
An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different Injection Sites in Adult Male and Female Subjects with Type 2 Diabetes and of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy, Normal Volunteers
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
Yes
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Walnut Creek, California, United States
GSK Investigational Site
Miramar, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Morrisville, North Carolina, United States
GSK Investigational Site
San Antonio, Texas, United States
Start Date
October 16, 2006
Primary Completion Date
March 20, 2007
Completion Date
March 20, 2007
Last Updated
September 11, 2017
63
ACTUAL participants
GSK716155 subcutaneous injections
DRUG
Lead Sponsor
GlaxoSmithKline
NCT06959901
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06861062